Soha R Youssef1, Esraa H Hassan2, Caroline S Morad3, Adel A Elazab Elged1,4, Rasha A El-Gamal1. 1. Clinical Pathology Department, Ain Shams University, Cairo, Egypt. 2. Regional Blood Transfusion Center, Cairo, Egypt. 3. Internal Medicine and Rheumatology Department, Ain Shams University, Cairo, Egypt. 4. Galala University, Suez, Egypt.
Abstract
PURPOSE: Erythroferrone (ERFE) is well acknowledged for its inhibitory function on hepcidin synthesis in the liver during stress erythropoiesis, thereby ensuring sufficient iron supply to bone marrow erythroblasts. Hepcidin plays an indispensable role in the pathogenesis of anemia of chronic disease (ACD). Thus, ERFE was suggested to protect against ACD in various diseases. Rheumatoid arthritis (RA) is commonly involved with ACD and high hepcidin levels, with a further increase of the latter in active states. The present study is a case-control study that aimed to determine the pattern of ERFE expression in RA patients with concomitant ACD and study its relationship with hepcidin, erythropoietin (EPO) and disease activity. PATIENTS AND METHODS: Fifty-five RA patients with ACD were categorized into active and inactive RA using the disease activity score (DAS28); 15 healthy subjects were included as control subjects. ERFE was measured for patients and control subjects using quantitative real-time polymerase chain reaction, in addition to testing for CBC, ESR, CRP, iron profile parameters and hepcidin. EPO was assessed for patients of both active and inactive RA groups. RESULTS: ERFE and hepcidin showed the highest levels in active RA; ERFE values were similar in control subjects and inactive RA patients, while hepcidin was significantly higher in inactive RA than control subjects. Patients with high ERFE levels had higher RBC, Hct, MCV, hepcidin and EPO levels. Stepwise regression analysis has identified DAS28 and disease duration as the best predictors of ERFE values, whereas ERFE and hepcidin were independent predictors of disease activity. CONCLUSION: We introduce ERFE as a novel marker of RA activity. Although the inhibitory effect of ERFE on hepcidin is not evident, our results still indicate that ERFE may have a beneficial erythropoietic effect in the context of ACD in RA disease activity.
PURPOSE: Erythroferrone (ERFE) is well acknowledged for its inhibitory function on hepcidin synthesis in the liver during stress erythropoiesis, thereby ensuring sufficient iron supply to bone marrow erythroblasts. Hepcidin plays an indispensable role in the pathogenesis of anemia of chronic disease (ACD). Thus, ERFE was suggested to protect against ACD in various diseases. Rheumatoid arthritis (RA) is commonly involved with ACD and high hepcidin levels, with a further increase of the latter in active states. The present study is a case-control study that aimed to determine the pattern of ERFE expression in RA patients with concomitant ACD and study its relationship with hepcidin, erythropoietin (EPO) and disease activity. PATIENTS AND METHODS: Fifty-five RA patients with ACD were categorized into active and inactive RA using the disease activity score (DAS28); 15 healthy subjects were included as control subjects. ERFE was measured for patients and control subjects using quantitative real-time polymerase chain reaction, in addition to testing for CBC, ESR, CRP, iron profile parameters and hepcidin. EPO was assessed for patients of both active and inactive RA groups. RESULTS: ERFE and hepcidin showed the highest levels in active RA; ERFE values were similar in control subjects and inactive RA patients, while hepcidin was significantly higher in inactive RA than control subjects. Patients with high ERFE levels had higher RBC, Hct, MCV, hepcidin and EPO levels. Stepwise regression analysis has identified DAS28 and disease duration as the best predictors of ERFE values, whereas ERFE and hepcidin were independent predictors of disease activity. CONCLUSION: We introduce ERFE as a novel marker of RA activity. Although the inhibitory effect of ERFE on hepcidin is not evident, our results still indicate that ERFE may have a beneficial erythropoietic effect in the context of ACD in RA disease activity.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Helen A Papadaki; Heraklis D Kritikos; Vasilis Valatas; Dimitrios T Boumpas; George D Eliopoulos Journal: Blood Date: 2002-07-15 Impact factor: 22.113
Authors: M A Gonzalez-Gay; J Llorca; M T Garcia-Unzueta; C Gonzalez-Juanatey; J M De Matias; J Martin; M Redelinghuys; A J Woodiwiss; G R Norton; P H Dessein Journal: Clin Exp Rheumatol Date: 2008 Jul-Aug Impact factor: 4.473
Authors: João Arezes; Niall Foy; Kirsty McHugh; Anagha Sawant; Doris Quinkert; Virginie Terraube; Alette Brinth; May Tam; Edward R LaVallie; Stephen Taylor; Andrew E Armitage; Sant-Rayn Pasricha; Orla Cunningham; Matthew Lambert; Simon J Draper; Reema Jasuja; Hal Drakesmith Journal: Blood Date: 2018-08-10 Impact factor: 22.113
Authors: Mark R Hanudel; Maxime Rappaport; Kristine Chua; Victoria Gabayan; Bo Qiao; Grace Jung; Isidro B Salusky; Tomas Ganz; Elizabeta Nemeth Journal: Haematologica Date: 2018-02-01 Impact factor: 11.047
Authors: G Wells; J-C Becker; J Teng; M Dougados; M Schiff; J Smolen; D Aletaha; P L C M van Riel Journal: Ann Rheum Dis Date: 2008-05-19 Impact factor: 19.103